Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations.
Francesco SaladiniAlessia GianniniAdele BoccutoFilippo DragoniAlice AppendinoEdoardo AlbanesiIlaria VicentiMaurizio ZazziPublished in: Antimicrobial agents and chemotherapy (2019)
Second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB) showed a high genetic barrier to resistance and limited cross-resistance with first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q148H/K/R plus one to two additional INSTI mutations.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- human immunodeficiency virus
- hiv testing
- hiv infected patients
- hiv aids
- hepatitis c virus
- men who have sex with men
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- escherichia coli
- peritoneal dialysis
- south africa
- genome wide
- gene expression
- copy number